Abstract Background: The Barcelona Clinic Liver Cancer (BCLC) intermediate and
advanced stages (BCLC B and C) of hepatocellular carcinoma (HCC) both include …

Sorafenib is used worldwide as a first-line standard systemic agent for advanced
hepatocellular carcinoma (HCC) on the basis of the results of two large-scale Phase III trials …

Aim Most patients with advanced hepatocellular carcinoma (HCC) have underlying chronic
liver disease, which potentially deteriorated the liver functional reserve that often affects the …

Hepatocellular carcinoma is one of the leading causes of cancer-related death both in
Japan and globally. In the advanced stage, hepatic arterial infusion chemotherapy (HAIC) is …

Background Patients with hepatocellular carcinoma (HCC) and Child–Pugh B liver cirrhosis
have poor prognosis and are underrepresented in clinical trials. The CELESTIAL trial, in …

Aim This study aimed to investigate liver functional reserves during sorafenib treatment for
advanced hepatocellular carcinoma (HCC), to identify predictive factors for maintaining …

Recent studies have shown that long non-coding RNAs (lncRNAs) play a pivotal role in the
pathogenesis and progression of hepatocellular carcinoma (HCC). However, the biological …

The comparative efficacy and safety between lenvatinib and hepatic artery infusion
chemotherapy (HAIC) in patients with unresectable hepatocellular carcinoma (HCC) is still …

Background: To date, the clinical management of advanced hepatocellular carcinoma
(HCC) patients remains challenging and the mechanisms of E2F transcription factor 1 …

Hepatocellular carcinoma (HCC) usually develops in chronically damaged liver. We
investigated hepatic reserves during chemotherapy of patients with advanced HCC and …